FY2025 EPS Estimates for AARD Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Aardvark Therapeutics down to ($2.84), a decrease from the previous estimate of ($2.46).
• Aardvark Therapeutics' stock has received mixed ratings, with one analyst downgrading it to "sell" while five others have maintained a "buy" rating, resulting in an average rating of "Moderate Buy".
• The company's stock recently traded down 4.3% and reported a quarterly loss of ($0.66 EPS, missing analysts' expectations of ($0.52).

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Aardvark Therapeutics in a research report issued to clients and investors on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($2.84) for the year, down from their prior forecast of ($2.46). Cantor Fitzgerald also issued estimates for Aardvark Therapeutics' FY2026 earnings at ($3.83) EPS.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.14).

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Royal Bank Of Canada lowered their target price on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research note on Thursday, August 14th. Finally, HC Wainwright assumed coverage on Aardvark Therapeutics in a research note on Monday, June 30th. They issued a "buy" rating and a $40.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $32.80.

Aardvark Therapeutics Stock Up 0.8%

NASDAQ:AARD traded up $0.08 during mid-day trading on Monday, reaching $9.75. 29,236 shares of the stock were exchanged, compared to its average volume of 85,567. The company has a 50 day moving average of $12.41. Aardvark Therapeutics has a 1 year low of $4.88 and a 1 year high of $19.58.

Hedge Funds Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics during the second quarter worth $42,000. Walleye Capital LLC acquired a new position in Aardvark Therapeutics during the first quarter worth $88,000. New York State Common Retirement Fund acquired a new position in Aardvark Therapeutics during the second quarter worth $99,000. Bank of America Corp DE raised its holdings in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock worth $108,000 after purchasing an additional 3,369 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Aardvark Therapeutics during the first quarter worth $153,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.